



General Assembly

January Session, 2023

**Raised Bill No. 6913**

LCO No. 6013



Referred to Committee on PUBLIC HEALTH

Introduced by:  
(PH)

***AN ACT CONCERNING OPIOIDS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective from passage*) A substance abuse treatment  
2 facility licensed as an institution pursuant to section 19a-490 of the  
3 general statutes shall (1) retain records regarding each person who  
4 receives treatment from the facility for not less than one year after the  
5 person last receives treatment, including, but not limited to, the person's  
6 address, telephone number and any additional contact information the  
7 person agrees to provide; (2) contact or attempt to contact the person for  
8 a status update on the person's physical and mental health not less than  
9 once every four months, for a period of not less than one year, after the  
10 person last received treatment from such facility; and (3) offer to or refer  
11 such person to additional substance use disorder treatment services if  
12 the person expresses a need or desire for such services.

13 Sec. 2. Section 10a-55t of the general statutes is repealed and the  
14 following is substituted in lieu thereof (*Effective from passage*):

15 (a) Not later than January 1, 2020, the president of each institution of

16 higher education in the state shall (1) develop and implement a policy  
17 consistent with subsection (b) of this section concerning the availability  
18 and use of opioid antagonists, as defined in section 17a-714, by students  
19 and employees of the institution, (2) submit such policy to the  
20 Department of Consumer Protection for approval, and (3) upon  
21 approval of the department, post such policy on the institution's Internet  
22 web site.

23 (b) The policy of each institution of higher education concerning the  
24 availability and use of opioid antagonists shall (1) designate a medical  
25 professional or public safety professional to oversee the purchase,  
26 storage and distribution of opioid antagonists on each of its campuses,  
27 (2) identify the location or locations on each of its campuses where the  
28 opioid antagonists are stored, which location or locations shall be made  
29 known and accessible to students and employees of such institution, (3)  
30 require maintenance of the supply of opioid antagonists in accordance  
31 with the manufacturer's guidelines, and (4) require a representative of  
32 the institution to call 911 or notify a local emergency medical services  
33 provider prior to, during or as soon as practicable after each use of an  
34 opioid antagonist on the institution's campus that is reported to the  
35 institution or observed by a medical professional or public safety  
36 professional, unless the person to whom the opioid antagonist was  
37 administered has already received medical treatment for his or her  
38 opioid-related drug overdose.

39 (c) Not later than January 1, 2024, the president of each institution of  
40 higher education shall report, in accordance with the provisions of  
41 section 11-4a, to the joint standing committees of the General Assembly  
42 having cognizance of matters relating to public health and higher  
43 education and employment advancement regarding the  
44 implementation of the policy concerning the availability and use of  
45 opioid antagonists on each campus.

46 Sec. 3. (NEW) (*Effective from passage*) (a) As used in this section:

47 (1) "Prescription digital therapeutic" means a software-based medical

48 device that (A) has been cleared or approved by the federal Food and  
49 Drug Administration, (B) is intended to prevent, manage or treat a  
50 substance use disorder, (C) a licensed health care provider prescribes for  
51 a patient, and (D) a patient may access through an application on a  
52 mobile device;

53 (2) "Licensed health care provider" means a licensed health care  
54 provider with experience treating patients with a substance use disorder  
55 who is authorized to prescribe a prescription digital therapeutic within  
56 the scope of such provider's practice;

57 (3) "Opioid use disorder" means a medical condition characterized by  
58 a problematic pattern of opioid use and misuse leading to clinically  
59 significant impairment or distress; and

60 (4) "Substance use disorder" means a pattern of use of alcohol or other  
61 substances that meets the applicable diagnostic criteria delineated in the  
62 most recent edition of the American Psychiatric Association's  
63 Diagnostic and Statistical Manual of Mental Disorders.

64 (b) Not later than January 1, 2024, the Department of Mental Health  
65 and Addiction Services, in collaboration with the Department of Public  
66 Health, shall establish a pilot program pursuant to which licensed  
67 health care providers may prescribe prescription digital therapeutics to  
68 patients with opioid use disorder or another substance use disorder for  
69 the management or treatment of such disorder. The Commissioners of  
70 Mental Health and Addiction Services and Public Health shall jointly  
71 develop eligibility criteria and guidelines for the pilot program. Such  
72 guidelines shall include, but need not be limited to, authorizing the  
73 provision of a prescription digital therapeutic for not less than a three-  
74 month period for up to one thousand such patients.

75 (c) Not later than January 1, 2025, the Commissioner of Mental Health  
76 and Addiction Services shall report, in accordance with the provisions  
77 of section 11-4a of the general statutes, to the joint standing committee  
78 of the General Assembly having cognizance of matters relating to public  
79 health on the implementation of the pilot program and any

80 recommendations for continuing or expanding the pilot program.

81 Sec. 4. Section 21a-317 of the general statutes is repealed and the  
82 following is substituted in lieu thereof (*Effective October 1, 2023*):

83 Every practitioner who distributes, administers or dispenses any  
84 controlled substance or who proposes to engage in distributing,  
85 prescribing, administering or dispensing any controlled substance  
86 within this state shall (1) obtain a certificate of registration issued by the  
87 Commissioner of Consumer Protection in accordance with the  
88 provisions of this chapter, (2) if the practitioner is engaged in  
89 prescribing a controlled substance, register for access to the electronic  
90 prescription drug monitoring program established pursuant to  
91 subsection (j) of section 21a-254 in a manner prescribed by the  
92 commissioner, and (3) if the practitioner is engaged in transporting a  
93 controlled substance for the purpose of treating a patient in a location  
94 that is different than the address that the practitioner provided to the  
95 Department of Consumer Protection as a registrant, as defined in section  
96 21a-240, notify the department, in a manner prescribed by the  
97 commissioner, of the intent to transport such controlled substance and,  
98 after dispensing such controlled substance, return any remaining  
99 amount of such controlled substance to a secure location at the address  
100 provided to the department. If the practitioner cannot return any  
101 remaining amount of such controlled substance to such address, the  
102 commissioner may approve an alternate location, provided such  
103 location is also approved by the federal Drug Enforcement Agency, or  
104 any successor agency. The practitioner shall report any dispensation by  
105 the practitioner of a controlled substance that occurs at a location other  
106 than the address provided to the department to the prescription drug  
107 monitoring program pursuant to subsection (j) of section 21a-254 upon  
108 returning to such address. No practitioner shall transport a controlled  
109 substance under subdivision (3) of this section to a location that is within  
110 five hundred feet of an elementary or secondary school ground, child  
111 care center, playground or public park, except a location that is a private  
112 residence where the dispensation of the controlled substance occurs  
113 inside such residence.

This act shall take effect as follows and shall amend the following sections:

Section 1	<i>from passage</i>	New section
Sec. 2	<i>from passage</i>	10a-55t
Sec. 3	<i>from passage</i>	New section
Sec. 4	<i>October 1, 2023</i>	21a-317

**Statement of Purpose:**

To combat the opioid pandemic.

*[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]*